{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:04:53Z","timestamp":1784653493287,"version":"3.55.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There are limited data to guide fertility counseling for patients on prolonged immune checkpoint inhibition. Concerns include potential teratogenicity, decline in ovarian reserve and spermatogenesis, and endocrine immune-related adverse events such as hypophysitis. As indications for checkpoint inhibition expand, an increasing number of reproductive-aged patients face fertility-related decisions around active therapy. We present two patient cases, one male and one female, who used assisted reproductive technology to support family building during maintenance immune checkpoint inhibitor therapy. A female lung cancer survivor underwent in vitro fertilization and froze six euploid blastocyst embryos for gestational surrogacy. A male gastroesophageal junction cancer survivor and his female partner underwent in vitro fertilization followed by a medicated intrauterine insemination cycle to conceive healthy fraternal twins. While prospective data are needed, this case series supports the feasibility of fertility treatment during checkpoint inhibitor therapy and highlights remaining clinical questions regarding this important aspect of cancer survivorship.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag273","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:47:31Z","timestamp":1784116051000},"source":"Crossref","is-referenced-by-count":0,"title":["Fertility treatment using assisted reproductive technology during immune checkpoint inhibition: report of two cases"],"prefix":"10.1093","volume":"31","author":[{"given":"Keri","family":"Tomechko","sequence":"first","affiliation":[{"name":"School of Medicine, University of California San Diego , San Diego, CA, 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3329-6381","authenticated-orcid":false,"given":"Tali","family":"Azenkot","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California , San Diego, CA, 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A","family":"Conway","sequence":"additional","affiliation":[{"name":"Utah Fertility Center , Utah,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip Pravin","family":"Patel","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California , San Diego, CA, 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Irene Su","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California , San Diego, CA, 92037,","place":["United States"]},{"name":"Obstetrics, Gynecology, and Reproductive Sciences, University of California , San Diego, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2026072112313326400_oyag273-B1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026072112313326400_oyag273-B2","doi-asserted-by":"crossref","first-page":"104064","DOI":"10.1016\/j.critrevonc.2023.104064","article-title":"Immune checkpoint inhibitors as a threat to reproductive function: a systematic review","volume":"188","author":"Tuerxun","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026072112313326400_oyag273-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"key":"2026072112313326400_oyag273-B4","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/humrep\/deaf096","article-title":"Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies","volume":"40","author":"Arecco","year":"2025","journal-title":"Hum Reprod"},{"key":"2026072112313326400_oyag273-B5","doi-asserted-by":"crossref","first-page":"oyag048","DOI":"10.1093\/oncolo\/oyag048","article-title":"Impact of immune checkpoint inhibition on ovarian reserve","volume":"31","author":"Buchbinder","year":"2026","journal-title":"Oncologist"},{"key":"2026072112313326400_oyag273-B6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","article-title":"Male fertility during and after immune checkpoint inhibitor therapy: a cross-sectional pilot study","volume":"152","author":"Salzmann","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026072112313326400_oyag273-B7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/cen.70001","article-title":"Testicular function after immune-checkpoint inhibitors treatment","volume":"103","author":"Boutros","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026072112313326400_oyag273-B8","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers16061176","article-title":"Immune checkpoint inhibitors and male fertility: Should fertility preservation options be considered before treatment?","volume":"16","author":"Ntemou","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026072112313326400_oyag273-B9","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1038\/s41598-025-91476-0","article-title":"Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system","volume":"15","author":"K\u00f6yl\u00fc","year":"2025","journal-title":"Sci Rep"},{"key":"2026072112313326400_oyag273-B10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2026072112313326400_oyag273-B11","doi-asserted-by":"crossref","first-page":"e245625","DOI":"10.1001\/jamanetworkopen.2024.5625","article-title":"Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns","volume":"7","author":"Gougis","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag273\/68969292\/oyag273.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag273\/68969292\/oyag273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag273\/68969292\/oyag273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:31:39Z","timestamp":1784651499000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag273\/8735231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag273","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,8]]},"article-number":"oyag273"}}